Understanding how CREB5 affects resistance to immune therapy in prostate cancer
Official title: Investigating CREB5-driven mechanisms of immune therapy resistance
Funded at Massachusetts General Hospital · NIH-11046940 · Data updated 2026-11-12
This study is looking at how a gene called CREB5 makes prostate cancer tougher against immune treatments, with the hope of finding better ways to help patients who aren't getting good results from these therapies.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Massachusetts General Hospital NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project start | December 11, 2024 |
| Project end | December 31, 2029 |
| Funding year | 2025 |
| Award (this year) | $620,820 |
| NIH project number | 1R01CA285582-01A1 |
| Project ID | NIH-11046940 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients with androgen-resistant prostate cancer who have not responded to immune checkpoint inhibitors.
✕Less likely to help
Patients with early-stage prostate cancer or those who have not yet undergone immunotherapy may not benefit from this research.
What this research studies
This research investigates the mechanisms by which the CREB5 gene contributes to resistance against immune therapies in prostate cancer. By utilizing advanced techniques like CRISPR screening, the study aims to identify how CREB5 influences tumor behavior and immune cell interactions, particularly focusing on its role in reducing the effectiveness of anti-PD-1 therapies. The goal is to uncover new strategies to enhance the response to immunotherapy for patients who currently do not benefit from these treatments.
Why it matters
Potential benefit: If successful, this research could lead to more effective immunotherapy options for prostate cancer patients who are resistant to current treatments.
How similar studies have gone: Previous research has shown promising results in understanding immune evasion mechanisms in cancer, suggesting that this approach could yield significant insights.
Where this research is happening
-
Massachusetts General Hospital
Boston, United States Active
Researchers
- Principal investigator: Manguso, Robert Thomas — Massachusetts General Hospital
- Study coordinator: Manguso, Robert Thomas
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.